Physician profile
Hong-Jun Chen
NPI 1871536060
$3,360.13
in general payments reported to CMS, 2019-2025
14 companies · $534 in 2025
The $534 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $161 · 2021: $450 · 2022: $434 · 2023: $983 · 2024: $517 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,034.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $747.11 | 2022-2024 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $673.40 | 2021-2025 | Ingrezza |
| Amgen INC. | $386.06 | 2023-2025 | Repatha, Evenity |
| Ibsa Pharma INC. | $282.36 | 2022-2024 | Licart |
| Gilead Sciences, INC. | $277.11 | 2022-2023 | Vemlidy |
| Avanir Pharmaceuticals, INC. | $268.20 | 2019 | |
| Abbvie INC. | $150.00 | 2025 | |
| Lilly USA, LLC | $134.60 | 2021-2025 | Kisunla |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2020 | |
| Axsome Therapeutics, INC. | $125.00 | 2023 | Auvelity |
| Horizon Therapeutics Plc | $35.51 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $18.86 | 2024 | Farxiga |
| Depuy Synthes Sales INC. | $11.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hong-Jun Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.